Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps

The United States market has remained flat over the past week but has shown a robust 21% increase over the last year, with earnings projected to grow by 14% annually. In this dynamic environment, identifying small-cap stocks like Anbio Biotechnology that possess strong growth potential and innovative capabilities can offer intriguing opportunities for investors seeking to uncover lesser-known gems.

Top 10 Undiscovered Gems With Strong Fundamentals In The United States

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Eagle Financial Services	125.65%	12.07%	2.64%	★★★★★★
Morris State Bancshares	9.72%	4.93%	6.51%	★★★★★★
Wilson Bank Holding	NA	7.87%	8.22%	★★★★★★
Omega Flex	NA	0.39%	2.57%	★★★★★★
Oakworth Capital	31.49%	14.78%	4.46%	★★★★★★
ASA Gold and Precious Metals	NA	7.47%	-26.86%	★★★★★★
Parker Drilling	46.05%	0.86%	52.25%	★★★★★★
Teekay	NA	-0.89%	62.53%	★★★★★★
Anbio Biotechnology	NA	8.43%	184.88%	★★★★★★
FRMO	0.08%	38.78%	45.85%	★★★★★☆

Click here to see the full list of 284 stocks from our US Undiscovered Gems With Strong Fundamentals screener.

Let's review some notable picks from our screened stocks.

Anbio Biotechnology (NasdaqGM:NNNN)

Simply Wall St Value Rating: ★★★★★★

Overview: Anbio Biotechnology specializes in providing in vitro diagnostics (IVD) products globally and has a market cap of $253.25 million.

Operations: Anbio Biotechnology generates revenue primarily from its Surgical & Medical Equipment segment, totaling $9.50 million.

Anbio Biotechnology, a nimble player in the biotech arena, has captured attention with its recent $8 million IPO and inclusion in the NASDAQ Composite Index. Over the past year, Anbio's earnings surged by 185%, outpacing industry growth of 37%. Despite being debt-free for five years and having high non-cash earnings, Anbio's shares remain highly illiquid. The company is making strides with innovative diagnostic solutions like its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000 and Point-of-Care Testing products showcased at Medlab Middle East 2025. These advancements position Anbio as a promising contender in rapid diagnostics.

• Get an in-depth perspective on Anbio Biotechnology's performance by reading our health report here.

• Learn about Anbio Biotechnology's historical performance.

DRDGOLD (NYSE:DRD)

Simply Wall St Value Rating: ★★★★★☆

Overview: DRDGOLD Limited is a gold mining company focused on extracting gold from the retreatment of surface mine tailings in South Africa, with a market capitalization of approximately $909.87 million.

Operations: DRDGOLD generates revenue primarily from its Ergo and FWGR operations, with Ergo contributing ZAR 5.05 billion and FWGR adding ZAR 2.02 billion. The company's financial performance is influenced by these segments, reflecting its focus on gold extraction from surface mine tailings in South Africa.

DRDGOLD, a notable player in the mining sector, showcases impressive financial strides with earnings surging 28% over the past year, outpacing industry growth. Trading at 83.4% below its estimated fair value, it presents a compelling valuation case. The company remains debt-free and has consistently maintained this status for five years, eliminating concerns over interest coverage. Recent results highlight robust sales of ZAR 3.8 billion and net income of ZAR 970 million for H1 2025 compared to ZAR 2.97 billion and ZAR 589 million last year respectively. A dividend increase to SA cents per share further underscores its financial health.

• Click to explore a detailed breakdown of our findings in DRDGOLD's health report.

• Evaluate DRDGOLD's historical performance by accessing our past performance report.

Northpointe Bancshares (NYSE:NPB)

Simply Wall St Value Rating: ★★★★★☆

Overview: Northpointe Bancshares, Inc., with a market cap of approximately $498.86 million, operates as the bank holding company for Northpointe Bank, offering a range of banking products and services.

Operations: Northpointe Bancshares generates revenue primarily through its Retail Banking segment, which contributes $134.42 million, and its Mortgage Warehouse (MPP) segment, adding $41.14 million.

With total assets of US$5.4 billion and equity of US$454.8 million, Northpointe Bancshares stands out with a robust financial structure. Its deposits reach US$3.5 billion, while loans amount to US$4.4 billion, showing a net interest margin of 2.3%. Despite revenue falling by 17%, earnings surged by 75% over the past year, surpassing industry averages significantly. The bank's allowance for bad loans is low at 18%, but non-performing loans are kept in check at just 1.5%. Trading at an attractive value—18% below estimated fair value—Northpointe seems poised for attention despite its illiquid shares and recent IPO activity raising US$151 million in February 2025.

• Click here and access our complete health analysis report to understand the dynamics of Northpointe Bancshares.

• Understand Northpointe Bancshares' track record by examining our Past report.

Northpointe Bancshares (NYSE:NPB)

Simply Wall St Value Rating: ★★★★★☆

Overview: Northpointe Bancshares, Inc., with a market cap of approximately $498.86 million, operates as the bank holding company for Northpointe Bank, offering a range of banking products and services.

Operations: Northpointe Bancshares generates revenue primarily from its Retail Banking segment, contributing $134.42 million, and the Mortgage Warehouse (MPP) segment, adding $41.14 million.

Northpointe Bancshares, with total assets of US$5.4 billion and equity of US$454.8 million, stands out due to its robust earnings growth of 75.1% over the past year, surpassing the banking industry's -2.3%. Despite a revenue drop of 17.3%, it trades at an attractive 18.2% below estimated fair value, suggesting potential undervaluation for investors seeking opportunities in smaller financial institutions. The bank's allowance for bad loans is low at 18%, while non-performing loans are appropriately managed at 1.5%. With deposits totaling US$3.5 billion and loans reaching US$4.4 billion, Northpointe's funding is primarily low-risk through customer deposits (72%).

• Click here to discover the nuances of Northpointe Bancshares with our detailed analytical health report.

• Examine Northpointe Bancshares' past performance report to understand how it has performed in the past.

Northpointe Bancshares (NYSE:NPB)

Simply Wall St Value Rating: ★★★★★☆

Overview: Northpointe Bancshares, Inc. is the bank holding company for Northpointe Bank, offering a range of banking products and services with a market capitalization of approximately $498.86 million.

Operations: Northpointe Bancshares generates revenue primarily from Retail Banking, contributing $134.42 million, and Mortgage Warehouse (MPP), adding $41.14 million. The company's market capitalization is approximately $498.86 million.

Northpointe Bancshares, with total assets of US$5.4 billion and equity of US$454.8 million, is trading at 18.2% below its estimated fair value, suggesting potential undervaluation. The bank has a solid foundation with US$3.5 billion in deposits and US$4.4 billion in loans, though the allowance for bad loans is low at 18%. Despite a revenue drop of 17.3%, earnings surged by 75.1%, outpacing the industry average decline of 2.3%. Recent IPO activity raised US$151 million, indicating strategic capital expansion efforts amidst its primarily low-risk funding structure comprising customer deposits (72%).

• Navigate through the intricacies of Northpointe Bancshares with our comprehensive health report here.

• Gain insights into Northpointe Bancshares' historical performance by reviewing our past performance report.

Northpointe Bancshares (NYSE:NPB)

Simply Wall St Value Rating: ★★★★★☆

Overview: Northpointe Bancshares, Inc. is the bank holding company for Northpointe Bank, offering a range of banking products and services with a market capitalization of approximately $498.86 million.

Operations: Northpointe Bancshares generates revenue primarily through its Retail Banking segment, contributing $134.42 million, and its Mortgage Warehouse (MPP) segment, adding $41.14 million.

Northpointe Bancshares, with total assets of US$5.4 billion and equity at US$454.8 million, is trading 18.2% below its estimated fair value, highlighting potential undervaluation. The bank's earnings growth of 75.1% over the past year significantly outpaced the industry average of -2.3%, showcasing robust performance despite a revenue decrease of 17.3%. With total deposits at US$3.5 billion and loans totaling US$4.4 billion, Northpointe maintains an appropriate level of non-performing loans at 1.5%. However, its allowance for bad loans remains low at 18%, indicating room for improvement in risk management strategies.

• Delve into the full analysis health report here for a deeper understanding of Northpointe Bancshares.

• Assess Northpointe Bancshares' past performance with our detailed historical performance reports.

Taking Advantage

• Unlock more gems! Our US Undiscovered Gems With Strong Fundamentals screener has unearthed 281 more companies for you to explore.Click here to unveil our expertly curated list of 284 US Undiscovered Gems With Strong Fundamentals.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com